Acta diabetologia latina

, Volume 24, Issue 4, pp 271–282 | Cite as

A longitudinal study of insulin antibodies and anti-insulin cytotoxicity in type I diabetes mellitus

  • Elizabeth R. Richens
  • Mary E. Seward
  • Martin Hartog
  • Wijdan A. Luqman
Original Contributions


Insulin antibodies and T-cell lymphocyte cytotoxic reactivity against insulin and its related peptides were studied longitudinally in 3 groups of patients with type I diabetes mellitus (DM). Group 1 patients were those in whom the diagnosis was made within 1 week of the initiation diagnosis. They were subdivided into those receiving MC porcine (A) or MC bovine (B) insulin. Group 2 patients were those with a duration of DM for 2–6 years who were receiving either MC porcine (A) or MC bovine (B) insulins. Group 3 subjects were those who had been on conventional recrystallized insulin and then switched to MC porcine (A) or MC bovine (B) insulins for 2 weeks before the start of the study. The incidence of cytotoxic reactions and insulin antibodies were approximately 40–50% for group 1 (either 1A or 1B) at the initiation of the study. At 3-month follow up all patients in group 1B developed insulin antibodies (p<0.02) and a significant increase in the frequency of cytotoxic reactions (p<0.01). By contrast there was a decline in the frequency of cytotoxic reactions in group 1A (p<0.01 at 1 year) and the increase in insulin antibodies was non-significant. Group 2B had higher frequency in cytotoxic reactions (p<0.005) and of insulin antibodies (p<0.05) than group 2A. A significant decrease (p<0.01) in cytotoxic reactions was observed at 3 months following the switch of patients from conventional bovine insulin preparations to ‘A’ but not to ‘B’. However in both subgroups insulin antibodies persisted for at least 12 months. Cross-reactivity between antibodies to human, porcine and bovine insulins was evident in all groups. The early cellular and humoral immune phenomena were positively correlated in both group 1A and 1B suggesting their common involvement in the pathogenesis of DM.


Insulin antibodies Insulin cytotoxicity Longitudinal study Type I diabetes mellitus 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Baskin B. L., Rosenthal A. S.: Determinant specific suppression of antigen induced T-cell proliferation in the guinea-pig. Quantitation of suppressed antigen-specific T-cell responses as a consequence of prior exposure to antigen in complete Freund’s adjuvant—J. Immunol.124, 184–193, 1980.PubMedGoogle Scholar
  2. 2.
    Bloom S. R., Barnes A. J., Adrian T. E., Polak J. M.: Autoimmunity in diabetics induced by hormonal contaminants of insulin—Lanceti, 14–17, 1979.Google Scholar
  3. 3.
    Dean B. M., Walker R., Bone A. J., Baird J. D., Cooke A.: Prediabetes in the spontaneously diabetic BB/E rat: lymphocyte subpopulations in the pancreatic infiltrate and expression of MHC class II molecules in endocrine cells—Diabetologia28 464–66, 1985.PubMedCrossRefGoogle Scholar
  4. 4.
    Diaz J.-L., Wilkin T.: Differences in epitope restriction of autoantibodies to native human insulin (1AA) and antibodies to heterologous insulin—Diabetes36, 66–72, 1987.PubMedCrossRefGoogle Scholar
  5. 5.
    Fairchild R. S., Kyner J. L., Abdou N. I.: Specific immunoregulation abnormality in insulin-dependent diabetes mellitus—J. Lab. clin. Med.99, 1975–78 1982.Google Scholar
  6. 6.
    Gepts W.: Pathology of IDDM in man. In:Mngola E. N. (Ed.): Diabetes, 1982. Excerpta Medica, Amsterdam—Oxford—Princeton, 1983; pp 99–107.Google Scholar
  7. 7.
    Iavicoli M., Pozzilli P., Di Mario U.: Increased lymphocyte transformation by insulin induced hypoglycaemia in normal subjects—J. clin. Lab. Immunol.1, 351–353, 1979.PubMedGoogle Scholar
  8. 8.
    Ionescu-Tîrgoviste C., Mincu I., Simionescu L., Cheta D., Mirondon Z., Sântu E., Popa E., Bîrnea A.: Disappearance rate of insulin antibodies after discontinuing insulin treatment in 42 Type 2 (non-insulin-dependent) diabetic patients—Diabetologia27, 592–5, 1984.PubMedCrossRefGoogle Scholar
  9. 9.
    Kaplan D. R., Colca J. R., McDaniel M. L.: Insulin as a surface marker on isolated cells from rat pancreatic islets—J. Cell Biol.97, 433–457, 1983.PubMedCrossRefGoogle Scholar
  10. 10.
    Kontiainen S.: Human insulin specific suppressor factors. Induction characteristics and comparison of murine factors—Clin. exp. Immunol.47, 715–724, 1982.PubMedGoogle Scholar
  11. 11.
    Kuhnau J., Rudiger H., Goetz K.: Circulating insulin antibodies during therapy with highly purified neutrally buffered insulins including desphe insulins—Exp. clin. Endocrinol.83, 161–7, 1984.PubMedCrossRefGoogle Scholar
  12. 12.
    Kurtz A. B., Gray R. S., Markanday S., Nabarro J. D. N.: Circulating IgG antibody to protamine in patients treated with protamine-insulins—Diabetologia25, 322–4, 1983.PubMedCrossRefGoogle Scholar
  13. 13.
    Kurtz A. B., Mathews J. A., Mustaffa B. E., Daggett P. K., Nabarro J. D. N.: Decrease of antibodies to insulin, proinsulin and contaminating hormones after changing treatment from conventional beef to purified pork insulin—Diabetologia18, 147–150, 1980.PubMedCrossRefGoogle Scholar
  14. 14.
    MacCuish A. C., Urbaniak S. J., Campbell C. J., Duncan L. J. P., Irvine W. J.: Phytohaemagglutinin transformation and circulating lymphocyte subpopulations in insulin dependent diabetic patients—Diabetes23, 708–710, 1974.PubMedGoogle Scholar
  15. 15.
    Mann D. L., Mendell N., Kahn C. R., Johnson A. H., Rosenthal A. S.:In vitro lymphocyte proliferation response to therapeutic insulin components. Evidence for genetic control by the human major histocompatibility complex—J. clin. Invest.72, 1130–1138 1983.PubMedGoogle Scholar
  16. 16.
    Palmer J. P., Asplin C. M., Clemens P., Lyen K., Tatpati O., Raghu P. K., Paquette T. L.: Insulin antibodies in insulin-dependent diabetics before insulin treatment— Science222, 1337–1339, 1983.PubMedCrossRefGoogle Scholar
  17. 17.
    Peacock I., Taylor A., Tattersall R. B., Douglas C. A., Reeves W. G.: Effects of new insulins on insulin and C-peptide antibodies, insulin dose and diabetic control—Lanceti, 149–152, 1983.CrossRefGoogle Scholar
  18. 18.
    Reeves W. G., Kelly U.: Insulin antibodies induced by bovine insulin therapy—Clin. exp. Immunol.50, 163–170, 1985.Google Scholar
  19. 19.
    Richens E. R., Luqman W., Groves R. W.: Reduced insulin binding by lymphoblastoid cell lines homozygous for HLA-DR3 and-DR4 genotypes. In:Jaworski M. A., Molnar G. D., Rajotte R. V., Singh B. (Eds): Immunology of diabetes. International Congress Series No. 717. Elsevier Science Publishers, Amsterdam, 1987; pp 263–267.Google Scholar
  20. 20.
    Richens E. R., Seward E. R., Groves R. W.: Cellular cytotoxicity to membrane-associated in an autologous system—Acta diabetol. lat.22, 55–62, 1985.PubMedCrossRefGoogle Scholar
  21. 21.
    Richens E. R., Seward M. E., Luqman W. A., Hartog M.: The human cellular immune response to insulin: a study in unexposed control subjects and type I diabetic patients on acute and chronic treatment—J. clin. Lab. Immunol.11, 135–141, 1983.Google Scholar
  22. 23.
    Schernthaner G., Borkenstein M., Fink M., Mayr W. R., Menzel J., Schober E.: Immunogenicity of human insulin (Novo) or pork monocomponent insulin in HLA-DR typed insulin-dependent diabetic individuals. In:Karam J. H., Etzwiler D. D. (Eds): International Symposium on Human Insulin. Diabetes Care6 (Suppl. 1), 43–8, 1983.Google Scholar
  23. 24.
    Thomas J. W., Virta V. J., Nell L. J.: Heterogeneity and specificity of human anti-insulin antibodies determined by isoelectric focusing—J. Immunol.134, 1048–52, 1985.PubMedGoogle Scholar
  24. 25.
    Wilkin T., Armitage M., Casey C., Pyke D. A., Hoskins P. J., Rodier M., Diaz J. L., Leslie R. D. G.: Value of insulin autoantibodies as serum markers for insulin-dependent diabetes mellitus—Lanceti, 430–483, 1985.Google Scholar
  25. 26.
    Wilkin T. J., Nicholson S.: Autoantibodies against human insulin—Brit. med. J.288, 249–352, 1984.CrossRefGoogle Scholar
  26. 27.
    Wilson R. M., Douglas C. A., Tattersall R. B., Reeves G. W.: Immunogenicity of highly purified bovine insulin: a comparison with conventional bovine and highly purified human insulins—Diabetologia28, 667–70, 1985.PubMedCrossRefGoogle Scholar

Copyright information

© Casa Editrice «il Ponte» 1987

Authors and Affiliations

  • Elizabeth R. Richens
    • 1
  • Mary E. Seward
    • 1
  • Martin Hartog
    • 2
  • Wijdan A. Luqman
    • 3
  1. 1.Department of PharmacologyUniversity of BathBath
  2. 2.University Department of MedicineUniversity of BristolBristolU.K.
  3. 3.Department of MedicineUniversity of IowaIowa CityU.S.A.

Personalised recommendations